India, Sept. 23 -- Genentech, affiliated to Swiss drug major Roche Holding AG (RHHBY,RO.SW,ROG.SW), and partner Ionis Pharmaceuticals, Inc. (IONS) announced Wednesday positive prespecified interim results from the ongoing Phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy or IgAN.
Roche licensed sefaxersen from Ionis for the treatment of complement mediated diseases.
IgAN, also known as Berger's disease, is a chronic and progressive autoimmune kidney disease, which is typically diagnosed in young adults. In the patients, up to 50% of people progress to kidney failure within 20 years, requiring dialysis or transplantation.
Proteinuria is a key indicator of kidney damage, and a reductio...